

## Institutional Biosafety Committee

Sep-05-2025, via Zoom

### Attendance

#### Members In Attendance

Member	Voting	Staff	Scientific	Affiliated
Cayabyab, Mark Ph.D.	Yes	Yes	Yes	Yes
Hillsley, Keisha M B.S.	Yes	No	No	No
Krueger, Robin Lynn Ph.D., M.P.H.	Yes	Yes	Yes	Yes
Murphy, Robert	Yes	No	No	No
Roldan, Janice M.B.A.	No	Yes	No	Yes
Smith, Robert PhD	Yes	Yes	Yes	Yes
Thompson, Jeffrey	Yes	Yes	Yes	Yes
Welmaker, Beth M.S.	Yes	Yes	Yes	Yes

### Review of Meeting Minutes

- Meeting Minutes (7 aye)

### Annual Renewal Submissions

#### 1. 2023-06-MC-02

**Titled:** Development of therapeutics against SARS-CoV-2 and HIV-1

**Discussion:**

- MC recused.

**Outcome:** Approved

**Votes for Outcome:** 6

**Votes Against Outcome:** 0

**Abstentions: 0**

**2. 2024-09-XH-01**

**Titled:** Targeting Autophagy in Oral Squamous Cell Carcinoma Immune Microenvironment

**Discussion:**

- MC recused.

**Outcome:** Approved

**Votes for Outcome:** 6

**Votes Against Outcome:** 0

**Abstentions:** 0

**3. 2024-09-UN-01**

**Titled:** Analysis of MDM2 regulation on AURKB in small cell lung cancer

**Discussion:**

**Outcome:** Approved

**Votes for Outcome:** 7

**Votes Against Outcome:** 0

**Abstentions:** 0

**4. 2024-10-NG-02**

**Titled:** Ketone Bodies-Mediated Cardiometabolic Adaptation via long noncoding RNAs

**Discussion:**

- Must provide a spec sheet from the commercial vendor.
- Did not provide the delivery system or formulation of the siRNA

**Outcome:** Approved Pending Modification(s)

**Votes for Outcome:** 7

**Votes Against Outcome:** 0

**Abstentions:** 0

**New Protocol Submissions**

**1. 2025-11-RG-01 (IBC New Submission)**

**Titled:** Designing a Potent STAT3 Inhibitor Through Molecular Docking, SAR Analysis, and Molecular/Biochemical Assay Validation

**Discussion:**

- Stat inhibitors - what are they using it for?
- Freezer location is missing (CCR468)
- For Personnel MJH, must identify a range of years of experience. "Several" is not appropriate.
- If cells will be purchased with STAT3-luc construct integrated, what virus work is required? If transduction is required, please outline procedures in SOP.
- Locked storage location is needed (CCR468)
- SOP related comments:
  - SOP is not in standard template format (recommend using standard template in the future)
  - Reporting incidents - should identify individuals and who they are reporting to
  - Biosafety practices - should include PPE (lab coat and gloves)
  - Safe work practices - is testing actually happening?
  - Sections 2 and 7 - confirm autoclave use and if not used remove reference
  - Section 4 - remove building to building transport since all work will occur in CCR
  - Emergency response to exposures - why is HIV a concern for commercially available 293 cells expressing stat3-luc? Recommend removal.
  - No experimental procedures to review and approve.

**Outcome:** Approved Pending Modification(s)

**Votes for Outcome:** 7

**Votes Against Outcome:** 0

**Abstentions:** 0

**2. 2025-10-LK-01 (IBC New Submission)**

**Titled:** Influence of 3D Printing Systems and Post-Processing Methods on Surface Properties, Mechanical Integrity, and Microbial Adhesion in Denture Bases

**Discussion:**

- PI must be added to the personnel list and provide personal training and experience information.
- BSC is confirmed to be at PI stated location.
- The SOP references BSL-1 in multiple areas, however these agents are to be handled in BSL-2. Title and date is also missing. Must correct inconsistency.

**Outcome:** Approved Pending Modification(s)

**Votes for Outcome:** 7

**Votes Against Outcome:** 0

**Abstentions:** 0

**3. 2025-08-Kawai-04 (IBC New Submission)**

**Titled:** Use of iPS cells in research

**Discussion:**

- SOP is missing title and date.
- MC recused.

**Outcome:** Approved Pending Modification(s)

**Votes for Outcome:** 6

**Votes Against Outcome:** 0

**Abstentions:** 0

**4. 2025-11-MSG-01 (IBC New Submission)**

**Titled:** Targeting a novel antisense lncRNA regulating muscarinic type 1 receptor:  
An Approach to augment the reduced protein level in Alzheimer's Disease

**Discussion:**

- Provide spec sheet from commercial vendor for cancer cell line to be used.

**Outcome:** Approved Pending Modification(s)

**Votes for Outcome:** 7

**Votes Against Outcome:** 0

**Abstentions:** 0

**Other Business**

- JR and BW have worked on editing the existing IBC Protocol form to add a Non Recombinant/Non RNA registration process. Individuals will use this form to submit their registration. This new section would not require full committee review but rather will only go through BSO review and approval.